Last updated on August 2019

First-In-Human Study of Monoclonal Antibody BMS-986218 by Itself and in Combination With Nivolumab in Patients With Advanced Solid Tumors

Brief description of study

The purpose of this study is to determine whether a Monoclonal Antibody both by itself and in combination with Nivolumab is safe and tolerable in the treatment of advanced solid tumors

Clinical Study Identifier: NCT03110107

Find a site near you

Start Over

H. Univ. Vall dHebron

Barcelona, Spain
  Connect »